By Derek Lowe Chemical News
This is not a paper that’s going to make everyone who reads it happy, but it needs to be read anyway. A collaboration between the University of Helsinki, LifeArc (which looks to be one of the small companies in the former Stevenage pharma campus) and Cyclofluidic reports development of inhibitors against hepsin, a serine protease enzyme that is a potential cancer target.
So far, so uncontroversial. The same group had identified a micromolar hepsin inhibitor from some late-1990s urokinase inhibitor chemical matter, but this compound (naturally) still had activity against urokinase. The goal was […]
Full Post at blogs.sciencemag.org